Table 2. Methotrexate Dosage regimen in Biologic Trials in RA.
| Author (year) | Biologic | MTX maximum dose mg/week | MTX mean dose mg/week | MTX route of administration |
|---|---|---|---|---|
| Bathon (2000) | ETN | 20 | 19 | Oral |
| Bong Lee (2014) | TOFA | 20 | 19 | Oral |
| Breedveld (2006) | ADA | 20 | 17 | Oral |
| Burmester (2015) | TCZ | 20 | 19 | Oral |
| Detert (2013) | ADA | 15 | 15 | Subcutaneous |
| Durez (2008) | INF | 20 | 20 | Oral |
| Emery (2008) | ETN | 20 | NR* * | Oral |
| Emery (2009) | GLM | 20 | 19 | Oral |
| Jones (2009) | TCZ | 20 | 16 | Oral |
| Smolen (2014) | ADA | 20 | NR** | Oral |
| St Clair (2004) | INF | 20 | 15 | Oral |
| Tak (2010) | RTX | 20 | >18 | Oral |
| Westhovens (2009) | ABA | 20 | 19 | Oral* |
ABA, abatacept; ADA, adalimumab; CZP, certolizumab; ETA, etanercept; GLM, golimumab; INF, infliximab; RTX, rituximab; TCZ, tocilizumab; TOFA, tofacitinib; NR, not reported; SC, subcutaneous.
In the Westhovens et al. trial 1.5% of subjects received injectable MTX, but it was not part of the protocol